Combined deletion of Pten and p53 in mammary epithelium accelerates triple‐negative breast cancer with dependency on e EF 2 K
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
The tumor suppressors Pten and p53 are frequently lost in breast cancer, yet the consequences of their combined inactivation are poorly understood. Here, we show that mammary‐specific deletion of Pten via WAP ‐Cre, which targets alveolar progenitors, induced tumors with shortened latency compared to those induced by MMTV ‐Cre, which targets basal/luminal progenitors. Combined Pten‐p53 mutations accelerated formation of claudin‐low, triple‐negative‐like breast cancer ( TNBC ) that exhibited hyper‐activated AKT signaling and more mesenchymal features relative to Pten or p53 single‐mutant tumors. Twenty‐four genes that were significantly and differentially expressed between WAP ‐Cre:Pten/p53 and MMTV ‐Cre:Pten/p53 tumors predicted poor survival for claudin‐low patients. Kinome screens identified eukaryotic elongation factor‐2 kinase ( eEF 2K) inhibitors as more potent than PI3K/ AKT / mTOR inhibitors on both mouse and human Pten/p53‐deficient TNBC cells. Sensitivity to eEF 2K inhibition correlated with AKT pathway activity. eEF 2K monotherapy suppressed growth of Pten/p53‐deficient TNBC xenografts in vivo and cooperated with doxorubicin to efficiently kill tumor cells in vitro . Our results identify a prognostic signature for claudin‐low patients and provide a rationale for using eEF 2K inhibitors for treatment of TNBC with elevated AKT signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Self-citationGuidelines for the use and interpretation of assays for monitoring autophagy
Klionsky, D. J., Abdalla, F. C., Abeliovich, H., Abraham, R. T., Acevedo-Arozena, A., Adeli, K., Agholme, L., Agnello, M., Agostinis, P., Aguirre-Ghiso, J. A., et al. (2012) · Autophagy · doi:10.4161/auto.19496 · Cited by 4,330 · cited 1×
“In accordance, suppression of autophagy by chloroquine (CQ), an inhibitor of autophagosome–lysosome fusion (Klionsky et al, 2012), revealed high autophagy flux (LC3-II accumulation) and efficient killing of both mouse and human Pten/p53-deficient tumor cells as compared to immortalized mammary…”
Self-citationNegative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551
Self-citationEnrichment Map: A Network-Based Method for Gene-Set Enrichment Visualization and Interpretation
Merico, D., Isserlin, R., Stueker, O., Emili, A., & Bader, G. D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013984 · Cited by 2,235 · cited 2×
“Supplementary information for this article is available online: http://embomolmed.embopress.org”
MethodSelf-citationThe clonal and mutational evolution spectrum of primary triple-negative breast cancers
Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., et al. (2012) · Nature · doi:10.1038/nature10933 · Cited by 1,967 · cited 2×
“…under the terms of the CC BY 4.0 license1542 In TNBC, p53 is deleted or mutated in 60–80% of cases (Holstege et al, 2010; Koboldt et al, 2012; Shah et al, 2012), whereas the Phosphatase and TENsin (Pten) homolog deleted in chromosome 10 (Li et al, 1997; Steck et al, 1997) is lost in 25–30%…”
BackgroundInfluentialPI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845
Debacq-Chainiaux, F., Erusalimsky, J. D., Campisi, J., & Toussaint, O. (2009) · Nature Protocols · doi:10.1038/nprot.2009.191 · Cited by 1,668
kConFab, Lim, E., Vaillant, F., Wu, D., Forrest, N. C., Pal, B., Hart, A. H., Asselin-Labat, M.-L., Gyorki, D. E., Ward, T., et al. (2009) · Nature Medicine · doi:10.1038/nm.2000 · Cited by 1,492 · cited 1×
“…cell-of-origin within the mammary epithelial cell hierarchy; claudin-low tumors are thought to arise from transformation of mammary stem cells, basal-like tumors from bi-potent/ early luminal progenitors, HER2+ BC from more committed luminal progenitors, etc. (Lim et al, 2009; Prat & Perou, 2009).”
BackgroundTimmerman, L. A., Holton, T., Yuneva, M., Louie, R. J., Padró, M., Daemen, A., Hu, M., Chan, D. A., Ethier, S. P., van ‘t Veer, L. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.020 · Cited by 573 · cited 1×
“…such as cytokeratin 14, and claudin-low/mesenchymal-like, expressing low levels of tight junction proteins including certain claudins and E-cadherin, and high levels of genes associated with epithelial-to-mesenchymal transition (EMT) (Prat et al, 2010; Lehmann et al, 2011; Timmerman et al, 2013).”
Background
Cited by
Stem Cells and the Differentiation Hierarchy in Mammary Gland Development
Fu, N. Y., Nolan, E., Lindeman, G. J., & Visvader, J. E. (2020) · Physiological Reviews · doi:10.1152/physrev.00040.2018 · Cited by 267
Liu, R., & Proud, C. G. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.123 · Cited by 117
Guestini, F., McNamara, K. M., Ishida, T., & Sasano, H. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1125469 · Cited by 58
Autophagy-related Proteins as a Prognostic Factor of Patients With Colorectal Cancer
Koustas, E., Sarantis, P., Theoharis, S., Saetta, A. A., Chatziandreou, I., Kyriakopoulou, G., Giannopoulou, I., Michelli, M., Schizas, D., Papavassiliou, A. G., et al. (2019) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000592 · Cited by 44
Rives-Quinto, N., Franco, M., de Torres-Jurado, A., & Carmena, A. (2017) · Development · doi:10.1242/dev.148171 · Cited by 26
“Given that cooperation between two oncogenes or two tumor suppressor genes can also lead to hyperplasia or neoplasia (Briggs et al., 2008; Land et al., 1983; Liu et al., 2014), we considered whether the simultaneous loss of scrib and cno in clones could lead to a tumor-like overgrowth.”
Background
Metadata
- Authors
- Liu, J. C., Voisin, V., Wang, S., Wang, D., Jones, R. A., Datti, A., Uehling, D., Al‐awar, R., Egan, S. E., Bader, G. D., Tsao, M., Mak, T. W., & Zacksenhaus, E.
- Venue
- EMBO Molecular Medicine
- Published
- 2014-10-20
- Volume
- 6
- Issue
- 12
- Pages
- 1542-1560
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2117847026
- Cited by
- 110
- References
- 13
- FWCI
- 5.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combined deletion of Pten and p53 in mammary epithelium accelerates triple‐negative breast cancer with dependency on e EF 2 K. https://app.cochat.ai/papers/10.15252/emmm.201404402
- The paper
- Liu, J. C., Voisin, V., Wang, S., Wang, D., Jones, R. A., Datti, A., Uehling, D., Al‐awar, R., Egan, S. E., Bader, G. D., Tsao, M., Mak, T. W., & Zacksenhaus, E. (2014). Combined deletion of Pten and p53 in mammary epithelium accelerates triple‐negative breast cancer with dependency on e EF 2 K. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201404402
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.